Implementing the EffTox dose-finding design in the Matchpoint trial


BACKGROUND The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the… (More)
DOI: 10.1186/s12874-017-0381-x


10 Figures and Tables

Cite this paper

@inproceedings{Brock2017ImplementingTE, title={Implementing the EffTox dose-finding design in the Matchpoint trial}, author={Kristian Brock and Lucinda Jane Billingham and Mhairi Copland and Shamyla Siddique and Mirjana Sirovica and Christina Gertrude Yap}, booktitle={BMC medical research methodology}, year={2017} }